Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber +4 more
wiley +1 more source
Association between postoperative nutritional status and time to initiation of adjuvant chemotherapy in gastrointestinal cancers: a restricted cubic spline analysis. [PDF]
Liu N +6 more
europepmc +1 more source
ABSTRACT Effective vaccines against Trypanosoma cruzi, the causative agent of Chagas disease, are urgently needed. Here, we report the design and in silico validation of a novel multiepitope vaccine construct targeting the key surface proteins ASP‐2 and gp82. Using a comprehensive immunoinformatics pipeline, we identified and selected 38 potent T‐cell (
Maria Karolaynne da Silva +8 more
wiley +1 more source
Clinical benefit of adjuvant chemotherapy in resected T2N0 distal cholangiocarcinoma: a retrospective cohort study. [PDF]
Chae YS +10 more
europepmc +1 more source
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Identification of Factors That Determine Adherence for Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer. [PDF]
Araradian C +7 more
europepmc +1 more source
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum +5 more
wiley +1 more source
Adjuvant Atezolizumab for Stage III Deficient Mismatch Repair Colon Cancer-Its Impact on Clinical Practice. [PDF]
Wu Y, Weng S, Yuan Y.
europepmc +1 more source
Aim In the GENESECT study, no significant gemcitabine (GEM) metabolism‐related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab‐paclitaxel, which has metabolic pathways different from GEM.
Takashi Yokokawa +21 more
wiley +1 more source
Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real-World Study. [PDF]
Ogawa I +17 more
europepmc +1 more source

